Deliver outcomes you demand
death or disabling stroke at 1 year in low risk patients1
Perfect the pathway through efficient procedures
of patients discharged the next day1*
Control for the future to continue to meet the emerging needs of new patient populations
successful post-TAVI coronary access3
*Study includes both SAPIEN XT and SAPIEN 3 valves.
Scroll / swipe side to side to review timeline
*As defined in the PARTNER 3 Trial: valve related, procedure related, cardiac related rehospitilisation.1
†These devices are not available for commercial supply in Australia and are shown for illustration purposes only.
Clinical Study
25,000+
patients studied in Edwards
Real world experience
660,000+
patients treated worldwide with Edwards TAVI valves
Data on file at Edwards Lifesciences.
References: 1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 2. Wood, D.A.; Lauck, S.B.; Cairns, J.A. et al. The Vancouver 3M (multidisciplinary, multimodality, but minimalist) clinical pathway facilitates safe next-day discharge home at low-, medium-, and high-volume transfemoral transcatheter aortic valve replacement centers: The 3M TAVI Study. J Am Coll Cardiol Intv. 2019. 3. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972. 4. Leon MB, Smith CR, Mack MJ, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. 5. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374(17):1609-1620. 6. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705. 7. Nazif T, Daniels D, McCabe J, Chehab B, et al. Real-world experience with the SAPIEN 3 Ultra TAVI: A propensity matched analysis from the United States. Presented virtually at TVT Connect 2020.
